Buy Recommendation for Anavex Life Sciences: Promising Alzheimer’s Treatment and Expanding Clinical Pipeline
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Anavex Life Sciences (AVXL – Research Report) today and set a price target of ...
bovnews5h
Cassava Sciences Inc (SAVA) Stock: Beyond the Surface of Its Performance?
On Tuesday, Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $3.83 which represents a decrease of $-0.47 or -10.93% from the prior close of $4.3. The stock opened at $4.32 and ...
Pharmabiz6h
Cassava Sciences’ ReThink-ALZ phase 3 study of simufilam in mild-to-moderate AD fails to meet co-primary endpoints
Cassava Sciences, Inc., a clinical-stage biotechnology company focused on developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, announced that the topline results from ...
ATTENTION SAVA SHAREHOLDERS: Investors who Lost Money on Cassava Sciences, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...
BioSpace14h
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
Cassava Sciences: Probably The End Of The Saga
Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...
A Controversial Alzheimer’s Drug Has Gone Down in Flames
Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...